Henoch-Schnlein purpura complicating adalimumab therapy for Crohn's disease

查看全文 作　　者：Farooq Z [1]Rahman;Gagandeep K [1]Takhar;Ovishek [1]Roy;Anna [2]Shepherd;Stuart L [1]Bloom;Sara A [1]McCartney

机构地区：[1]Department of Gastroenterology,University College London Hospitals NHS Foundation Trust,London,NW1 2BU,United Kingdom;[2]Department of Histopathology,University College London Hospitals NHS Foundation Trust,London,NW1 2BU,United Kingdom

出　　处：《World Journal of Gastrointestinal Pharmacology and Therapeutics》索引2010年第1卷第5期,共4页

摘　　要：Anti-tumour necrosis factor-α(TNF) therapy has revolutionised the management of chronic inflammatory conditions.With ever increasing numbers of patients being treated with these agents,uncommon adverse reactions will inevitably occur more frequently.Cutaneous manifestations are associated with many of these chronic conditions and can complicate anti-TNF therapy in about 20% of cases.Vasculitic complications are rarely associated with anti-TNF therapy.Henoch-Schnlein purpura(HSP),a small vessel vasculitis,has been described following infliximab and etanercept therapy but never with adalimumab,a fully humanized TNF antibody.The risk of such immune-mediated reactions is theoretically less with adalimumab compared to infliximab but can still occur.Here we report the f irst case in the literature of HSP that can be attributed to the use of adalimumab in a 19-year-old male with recalcitrant Crohn's disease. 关键词：Henoch-Schnlein purpura ADALIMUMAB Anti-TNF THERAPY Leukocytoclastic vasculitis Crohn’s disease

相关文献

参考文献（2）
引证文献（2）
耦合文献（3）

参考文献(2)

引证文献(2)

耦合文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Henoch-Schnlein purpura complicating adalimumab therapy for Crohn's disease

参考文献(2)

引证文献(2)

耦合文献(3)

用户提示